THE PROPERTIES OF 8-ISOPROSTAGLANDIN AND ITS RELATIONSHIP WITH OXIDATIVE STRESS IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE (review and own research)

Authors

  • Kravchun N. O. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv
  • Dorosh O. G. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv
  • Ovsyannikova T. M. V. Karazin Kharkiv National University
  • Alekseeva I. I. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2014.1.08

Keywords:

non-alcoholic fatty liver disease, type 2 diabetes mellitus, lipid peroxidation, oxidative stress, 8-isoprostaglandin.

Abstract

Presented an overview of scientific publications concerning of the role of prostaglandins as important physiologically active body substance that have antiviral and antitumor activity, as well as potential local regulators of cellular immunity. Results of the authors research have demonstrated varying degrees of activity 8-isoprostaglandin in patients with type 2 diabetes mellitus (DM) in combination with non-alcoholic fatty liver disease (NAFLD). It was found that the middle level of 8-isoprostaglandin in patients with comorbid pathology is significantly higher than in healthy individuals and patients with type 2 diabetes without liver disease, but it was significantly lower in the group of patients with initial manifestations of NAFLD.

References

Mashkovskij MD. Farmakologija 1972; 1:109-115.

Sergeev PV. Biohimicheskaja farmakologija, Moskva, 1982: 517 p.

Lahvich FA, Pashkovskij FS, Koroleva EV. Uspehi Himii 1992; 61(2): 456-495.

Varfolomeev SD, Mevh AT. Prostaglandiny — molekuljarnye bioreguljatory, Moskva, 1985: 308 p.

Gubich OI, et al. Himija, struktura i funkcija biomolekul: tezisy II mezhdunar. konf., Minsk, 2006:PR-40.

Azhgihin IS. Prostaglandiny, Moskva, 1978: 416 p.

Novik GA. Mehanizmy allergicheskih reakcij i metody allergoobsledovanija v klinicheskoj praktike, pod red. IM.Voroncova, Sankt-Peterburg, 2004: 77 p.

Santoro MG, Benedetto A, Carruba G. Science 1980; 209:1032-1034.

Straus DS, Glass CK. Med Res Rev 2001; 21(3):185-210.

Coleman RA, Smith WL, Narumiya S. Pharmacol Rev 2001; 46(2):205-229.

Ma X, et al. Cancer Res 2006; 66(6):2923-2927.

Straus DS, Pang KJ. Exp Cell Res 1984; 151:87-95.

Niho N, et al. Cancer Sci 2005; 96(5):260-264.

Cornelussen RNM, Gupta S, Knowlton AA. J Mol Cell Cardiol 2001; 33:1447-1454.

Rappoport RS, Dodge GR. J Exp Med 1982; 155:943-948.

Parnova RG. Biol Membrany 1999; 16(2):230-239.

Peljuh PF. Vlijanie prostaglandinov E2 i F2 alpha na jelektricheskuju i mehanicheskuju aktivnost’ gladkih myshc mochetochnika morskoj svinki, L’vov, 1991:17 p.

Corla N, et al. Br J Exp Pathol 1983; 64(4):388-395.

Coleman RA, Smith WL, Narumiya S. Pharmacol Rev 2001; 46(2):205-229.

Zayika MN, Kovalyova ON. Sixteen European Meeting on Hypertension, Madrid, 2006: 341.

Duncombe WC. Biochem J 1963; 188(1):7-10.

Torer N, Ozenirler S, Yucel A, et al. Scand J Gastroenterol 2007; 42(9): 1095-1101.

Milner K, Van der Poorten D, Xu A, et al. Hepatology 2009; 49(6): 1926-1934.

Kawata S. Clin J Gastroenterol 2008; 1(1):1-6.

Ametov AS. Saharnyj diabet 2 tipa. Problemy i reshenija, Moskva, 2012: 704 p.

Kozak BM, Tjota MY, Close KL. J Diabetes 2013; 4:8-17.

Hvorostinka VM, Vlasenko AV. Mezhdunar Jendokrinol Zhurn 2007; 5(11):65-70.

Myhal’chuk LM, Jefimov AS. Mezhdunar Jendokrinol Zhurn 2010; 2:1-12.

Saharnyj diabet: diagnostika, lechenie, profilaktika, pod red. II. Dedova, MV. Shestakovoj, Moskva, 2011: 808 p.

Day CP, James OFW. Gastroenterology 1998; 114:842-45.

Garc MC. J Gastroenterol Hepatol 2001; 24:395-402.

Fassio E, Alvarez E, Dominguez N, et al. Hepatology 2004; 40(4):820-826.

Vendemiale G, Grattagliano I, Caraceni P, et al. Hepatology 2001; 33: 808-815.

El’chaninova SA, Galaktionova LP, Tolmacheva NV, et al. Terapevt Arh 2000; 4:51-53.

Vladimirov JuA, Archakov AI. Perekisnoe okislenie lipidov v biologicheskih membranah, Moskva, 1972: 252 p.

Vladimirov JuA. Sorosovskij Obrazovat Zhurn 2000; 6(12):13-19.

Cracowski JL, Stanke-Labesque F, Bessard G. Rev Med Intern 2000; 21: 304-307.

Ciabattoni G, Consoli A, Vitacolonna E, et al. Thromb Haemost 1998; 29:232-233.

Lawson JA, Rokach J, FitzGerald GA. J Biological Chem 1999; 274: 24441-24444.

Greco A, Mingetti L, Levi G. Neurochem Res 2000; 25:1357-1364.

Meydani M. Nutr Rev 1997; 55:404-407.

Polivoda SN, Cherepok AA, Sychev RA. Krovoobig ta Gemostaz 2005; 2: 34-39.

Tacconelli S, Capone ML, Patrignani P. Methods Mol Biol 2010; 644: 165-178.

Elesber AA, Best PJ, Lennon RJ, et al. Free Radic Res 2006; 40(4):385-391.

Decideri G, Ferry C. JAMA 2003; 289:1781-1782.

Gerasimchuk NN, Kovaljova ON, Safargalina-Kornilova NA. Kardiovaskuljarnaja Terapija i Profilaktika 2012; 11:33.

Xu W, Shao L, Zhou C, et al. Hepatogastroenterology 2011; 58(112): 2077-80.

Shi GX, Liu CZ, Wang LP, et al. Can J Neurol Sci 2012; 39(1):65-68.

Hakim IA, Harris R, Garland CA, et al. Cancer Epidemol Biomarkers Prev 2012; 21(12):2193-200.

Downloads

Published

2014-03-12

How to Cite

Kravchun, N. O., Dorosh, O. G., Ovsyannikova, T. M., & Alekseeva, I. I. (2014). THE PROPERTIES OF 8-ISOPROSTAGLANDIN AND ITS RELATIONSHIP WITH OXIDATIVE STRESS IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE (review and own research) . Problems of Endocrine Pathology, 47(1), 63-71. https://doi.org/10.21856/j-PEP.2014.1.08

Most read articles by the same author(s)

1 2 > >>